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Abstract
Insulin like growth factor binding protein two (IGFBP-2) is important for acquisition of normal 
bone mass in mice; however, the mechanism by which IGFBP-2 functions is not defined. These 
studies investigated the role of IGFBP-2 in stimulating osteoblast differentiation. MC-3T3 
preosteoblasts expressed IGFBP-2, and IGFBP-2 knockdown resulted in a substantial delay in 
osteoblast differentiation, reduced osteocalcin expression and Alizarin red staining. These findings 
were replicated in primary calvarial osteoblasts obtained from IGFBP-2 −/− mice and addition of 
IGFBP-2 rescued the differentiation program. In contrast, overexpression of IGFBP-2 accelerated 
the time course of differentiation as well as increasing the total number of differentiating cells. By 
day 6 IGFBP-2 overexpressing cells expressed twice as much osteocalcin as control cultures and 
this difference persisted. To determine the mechanism by which IGFBP-2 functions, the 
interaction between IGFBP-2 and receptor tyrosine phosphatase β (RPTPβ) was examined. 
Disruption of this interaction inhibited the ability of IGFBP-2 to stimulate AKT activation and 
osteoblast differentiation. Knockdown of RPTPβ enhanced osteoblast differentiation whereas 
overexpression of RPTPβ was inhibitory. Adding back IGFBP-2 to RPTPβ overexpressing cells 
was able to rescue cell differentiation via enhancement of AKT activation. To determine the region 
of IGFBP-2 that mediated this effect an IGFBP-2 mutant that contained substitutions of key amino 
acids in the heparin binding domain-1 (HBD-1) was prepared. This mutant had a major reduction 
in its ability to stimulate differentiation of calvarial osteoblasts from IGFBP-2 −/− mice. Addition 
of a synthetic peptide that contained the HBD-1 sequence to calvarial osteoblasts from IGFBP-2 −/
− mice rescued differentiation and osteocalcin expression. In summary, the results clearly 
demonstrate that IGFBP-2 stimulates osteoblast differentiation and that this effect is mediated 
through its heparin binding domain-1 interacting with RPTPβ. The results suggest that stimulation 
of differentiation is an important mechanism by which IGFBP-2 regulates the acquisition of 
normal bone mass in mice.
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Introduction
IGFBP-2 is a member of a family of six IGF binding proteins. Although a major function of 
this class of proteins is to transport the IGFs through the circulation and extracellular fluids, 
thereby restricting their access to receptors, each form of binding protein has been found to 
have distinct actions.(1) Initial studies showed that IGFBP-2 can enhance the effect of IGF-II 
to stimulate alkaline phosphatase in bone cell cultures.(2) When IGFBP-2 gene expression 
was deleted in mice, tibial bone volume was reduced and both micro CT and pQCT analysis 
showed diminished trabecular number and volume.(3) A subsequent study defined a 13 
amino acid region of IGFBP-2 (termed HBD-1) that was required for biologic activity. 
Substitution of key residues within this region resulted in loss of the ability of IGFBP-2 to 
stimulate osteoblast proliferation in vitro.(4) Importantly when a synthetic peptide containing 
the HBD-1 sequence was injected into the IGFBP-2 −/− mice, micro CT analysis showed 
that trabecular volume and density could be rescued.(4) Furthermore this peptide was shown 
to stimulate osteoblast proliferation in vivo.
Prior studies have suggested that IGF-I and IGFBP-2 play a role in osteoblast differentiation. 
Cell type specific deletion of IGF-I in osteoblasts resulted in decreased femoral BMD and 
decreased bone formation rate.(5) Some studies have suggested a correlation between 
IGFBP-2 and osteoblast differentiation. During induction of differentiation in the osteoblast 
sheets, analysis of gene expression profiles showed that IGFBP-2 is one of the genes that 
showed the greater increase.(6) PTH increases IGFBP-2 expression in differentiated 
osteoblasts.(7) Finally mesenchymal stromal cells can be made to further differentiate into 
osteoblasts with dexamethasone and this requires the interaction of the α5 integrin and 
IGFBP-2.(8)
Although recent studies have documented the importance of the HBD-1 domain of IGFBP-2 
for osteoblast growth, the relative importance of this domain for osteoblast differentiation 
has not been determined. A recent study demonstrated that the HBD-1 region bound directly 
to a cell surface receptor termed receptor tyrosine phosphatase β and that RPTP-β was 
expressed by MC-3T3 cells.(9) It further demonstrated that IGFBP-2 binding to this receptor 
induced RPTPβ dimerization which inhibited its phosphatase activity. Since the primary 
substrate of this phosphatase was shown to be PTEN, subsequent analysis showed that 
engagement of this receptor on osteoblast surfaces resulted in enhanced tyrosine 
phosphorylation of PTEN which inhibited its activity. This was associated with increased 
AKT activation. These data imply that IGFBP-2 may be functioning directly to augment 
constitutive AKT activation in osteoblasts. Since AKT activation has been linked to 
osteoblast differentiation(10), the current studies were undertaken to determine if IGFBP-2 
could directly stimulate osteoblast differentiation, if it was functioning through interaction 
with RPTPβ and if this interaction was mediated through the HBD-1 domain.
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Human IGF-I was a gift from Genentech (South San Francisco, CA). Immobilon-P 
membrane, LY294002 and PD98059 were purchased from EMDmillipore Corp. (Billerica, 
MA). α-MEM, streptomycin and penicillin were purchased from Life Technologies (Grand 
Island, NY). Anti-RPTPβ antibody was purchased from BD Bioscience (San Diego, CA). 
Antibodies against phospho-AKT (S473), pErk1/2, cleaved caspase-3 and PTEN were 
purchased from Cell Signaling Technology Inc. (Beverly, MA). Anti-phospho-tyrosine 
(PY99), osteocalcin, β-actin antibodies were purchased from Santa Cruz Biotechnology, Inc. 
(Santa Cruz, CA). PQ401 was purchased from TOCRIS bioscience (Bristol, United 
Kindom). IGFBP-2 antiserum was prepared as previously described.(11) The horseradish 
peroxidase-conjugated mouse anti-rabbit, goat anti-mouse, and mouse anti-rabbit light 
chain-specific antibodies were purchased from Jackson ImmunoResearch Laboratories 
(West Grove, PA). All other reagents were obtained from Sigma unless otherwise stated. The 
synthetic peptide containing the linker located heparin-binding domain of IGFBP-2 
(188KHLSLEEPKKLRP200) (referred to as HBD-1 peptide) and a scrambled HBD peptide 
(CKPLRLSKEEHPLK) (referred to as HBD control peptide), were synthesized by the 
Protein Chemistry Core Facility at the University of North Carolina at Chapel Hill. Purity 
and the sequences were confirmed by mass spectrometry.
Mice
Generation of the original mixed background strain B6;129-Igfbp2<tm1Jep>, which we 
refer to as Igfbp2−/− mice, has been described previously.(3) The original mice were 
backcrossed onto C57BL/6J background for 10 generations. Igfbp2+/+ mice were C57BL/6J 
controls. All of the experimental studies were performed with male mice. All of the animal 
studies were reviewed and approved by the Institutional Animal Care and Use Committee of 
University of North Carolina at Chapel Hill.
Cell culture
MC-3T3 E1 clone 4 (CL4) cells were obtained from ATCC (Manassas, VA). Cells were 
cultured in α-MEM (glucose 1000mg/L) containing 10% fetal bovine serum (Thermo 
Fishers Scientific, Pittsburgh, PA). After confluency, culture medium was changed to 
differentiation medium (DM) which contained 10% fetal bovine serum plus 50 ug/ml 
ascorbic acid and 4 mM β-glycerol phosphate. Fresh DM was applied every 72 hr. IGFBP-2 
(1 ug/ml), HBD-1 (1ug/ml or as stated), control peptide (1ug/ml) or HBD mutant IGFBP-2 
(1 ug/ml) were added to the differentiation medium, and replaced every 72 hr.
Neonatal calvarial osteoblasts were isolated from 3–5-day-old mice. Briefly, calvariae were 
digested five times with collagenase type 2 (250 unit/ml) and trypsin (0.05%) plus EDTA 
(0.02%) in the PBS. The cells released from digests 2–5 were collected as primary calvarial 
osteoblasts and maintained in DMEM (glucose 1000 mg/L) supplemented with 10% FBS 
and nonessential amino acids.
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Construction of cDNAs and establishment of MC3T3 cells expressing wild type IGFBP-2, 
RPTPβ and LacZ
Mouse IGFBP-2 cDNA was amplified from mouse pCMV-SPORT6 (ATCC, Manassas, VA) 
using a 5′ primer sequence corresponding to nucleotides 89 to 110 of mouse IGFBP-2 (5′-
ATGCTGCCGAGATTGGGCGGCC-3′) and a 3′ primer sequence complementary to 
nucleotides 981 to 1003 (5′-GGGCCCATGCCCAAAGTGTGCAG-3′). After DNA 
sequencing to confirm that the correct sequence had been amplified, the PCR product was 
subcloned into pENTR/D-TOPO vector and subsequently transferred into the pLenti6-V5 
DEST expression vector using the LR Clonase reaction and following the manufacturer's 
instructions (Life Technologies, Grand Island, NY). Constructions of RPTPβ and LacZ have 
been described previously.(9) The constructs contained the correct sequences was verified by 
DNA sequencing. 293FT cells (Life Technologies, Grand Island, NY) were prepared for 
generation of virus stocks and CL4 expressing IGFBP-2, RPTPβ and LacZ were established 
using procedures that have been described previously.(12)
Construction of cDNAs and establishment of IGFBP-2 Si, RPTPβ Si and LacZ Si cells
Based on Life Technologies’ website design tools, a sequence containing 21 
oligonucleotides (GGAAAGAGACCAACACTGAGC) was used to construct the shRNA 
template plasmid to inhibit the translation of mouse IGFBP-2 mRNA. 
GCCAATGCATACAGCAGTAAT was used to construct the shRNA template to knock down 
mouse RPTPβ. The oligonucleotides were synthesized by Nucleic Acids Core Facility at 
UNC, annealed and ligated into BLOCK-iT™ U6 RNAi Entry Vector (Cat# K4945-00, Life 
Technologies, Grand Island, NY) following manufacturer’s instructions. The complete 
sequence was verified by DNA sequencing. The expression vector was generated using the 
Gateway LR recombination reaction between the Entry Vector and BLOCK-iT™ Lentiviral 
RNAi Gateway® Vector (Cat# K4943-00, Life Technologies, Grand Island, NY). A 
sequence targeting LacZ was used as a control. After confirmation of the sequence, plasmid 
DNA was prepared using a Plasmid Midi Kit (Promega, Madison, WI). 293FT cells (Life 
Technologies, Grand Island, NY) were transfected and used to prepare for generation of 
virus stocks.(12) CL4 cells expressing small hairpin RNA sequence targeting IGFBP-2 
(IGFBP-2 Si), RPTPβ (RPTPβ Si) and corresponding control CL4 expressing small hairpin 
RNA sequence targeting LacZ (LacZ Si) were established using procedures described 
previously.(12)
Immunoprecipitation and Immunoblotting
The cell monolayers were lysed in a modified radioimmunoprecipitation assay (RIPA) buffer 
as previously described.(12) Immunoprecipitation was performed by incubating 0.5 mg of 
cell lysate protein with 1 ug of each of the following antibodies: anti-IGFBP-2 and PY99 at 
4°C overnight. Immunoblotting was performed as previously described(12) using a dilution 
1:1000 for anti-pAKT (Ser473), PTEN and β-actin antibodies, a dilution 1:500 for anti-
RPTPβ antibody, a dilution 1:200 for anti-osteocalcin antibody and a dilution 1:10000 for 
anti-IGFBP-2 antibody. The proteins were visualized using enhanced chemiluminescence 
(Thermo Fisher Scientific, Rockford, IL). Total cellular protein in the lysates was 
determined using BCA (Thermo Fisher Scientific, Rockford, IL).
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Cells were washed with PBS twice before were fixed with 10% formalin. After 10 min 
fixation, 1% Alizarin Red (pH 4.2) was applied and incubated for another 10 min before it 
was removed. Cells were washed with ddH2O twice and drying. Images were captured using 
Leica M420 Microscope.
RNA isolation and quantitative real-time PCR
Total RNA was prepared using RNeasy plus mini kit (Qiagen, Valencia, CA, USA) for 
cellular extracts. cDNA was then generated from 500 ng of RNA using the High Capacity 
cDNA Reverse Transcription Kit (Applied Biosystems) per the manufacturer’s instructions. 
Quantitative real-time expression analysis was run on the CFX384 Real-time System using 
the iQ SYBR Green Supermix and C1000 thermal Cycler (Bio-Rad, Hercules, CA, USA). 
Relative expression of mRNA was determined after normalization to Hprt levels using the 
ΔCt method. Primers were designed, sequenced and validated to be 95% to 100% efficient 
by Primer Design Ltd (Southampton, UK). All primer sequences are listed in Supplementary 
Table 1.
Cell proliferation and apoptosis assay
Calvarial osteoblasts isolated from IGFBP-2 −/− mice were seeded in 6 well plate. After 
reaching confluency the culture medium was changed to DM or DM plus HBD-1 or DM 
plus IGFBP-2. Control cells and IGFBP-2 overexpressing cells were plated in 24 well plates 
using the same plating density. After reaching confluency the culture medium was changed 
to DM. Fresh DM was applied every 72 hr. After cells were exposed to DM for indicated 
days, the cells were released with 0.05% Trypsin-EDTA and counted.
To quantify apoptosis, calvarial osteoblasts isolated from IGFBP-2 −/− mice were exposed 
to DM alone or DM plus the different concentrations of HBD-1 peptide for 21 days. Cell 
lysates were harvested as described previously and immunoblotted using an anti-cleaved 
caspase-3 antibody.
Statistical analysis
Densitometry results are expressed as the mean ± standard deviation (SD). All experiments 
were replicated at least three times to assure reproducibility. The results were analyzed for 
statistically significant differences using Student’s t-test or analysis of variance followed by 
Bonferroni multiple comparison post hoc test. Statistical significance was set at p<0.05.
Results
IGFBP-2 stimulates osteoblast differentiation
Since we had shown that IGFBP-2 enhances AKT activation in osteoblasts,(9) we 
determined if IGFBP-2 regulates osteoblast differentiation. MC-3T3 cells have been shown 
to secrete IGFBP-2 and its secretion increases significantly between day 6 and 9 following 
the addition of differentiation medium. RNAi was used to determine the significance of 
these changes and if inhibiting IGFBP-2 synthesis would alter differentiation (Fig 1A). 
Compared to control cultures the differentiation of MC-3T3 cells in which IGFBP-2 
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synthesis had been inhibited was significantly attenuated. Both osteocalcin expression (Fig 
1B) and the number of alizarin red positive cells were reduced (Fig 1C).
To confirm the importance of IGFBP-2 for differentiation of preosteoblasts, calvarial pre-
osteoblasts, isolated from IGFBP-2 −/− mice were analyzed. These cells showed impaired 
osteocalcin expression and differentiation compared to cells from control littermates (Fig 
1D) (e.g., a 2.3 ± 0.1 fold greater level of osteocalcin in control cells on day 21, compared to 
IGFBP-2 −/− cells, p<0.01). The time course of differentiation was prolonged in cultures 
from the IGFBP-2 −/− mice and only 1.8 ± 0.2% cells had completed differentiation by day 
21 (Fig 1E). The addition of IGFBP-2 to these cultures restored differentiation (Fig 1E). In 
contrast, overexpression of IGFBP-2 in MC-3T3 cells significantly enhanced the osteocalcin 
expression (Fig 1G) (e.g., a 2.5 ± 0.1 fold greater level of osteocalcin on day 6 compared to 
control cultures, p<0.05). In addition, in IGFBP-2 overexpressing cells osteocalcin was 
detected on day 3 whereas it was detected on day 6 following the addition of differentiation 
medium in control cells (Fig 1G). Major differences in osteocalcin expression were detected 
at each time point and persisted up to day 21. In addition alizarin red positive cells were 
detected on day 6 in IGFBP-2 overexpressing cells whereas they were not detected until day 
15 in control cells (Fig 1H). To confirm these results, we analyzed the expression of several 
genes that are important for osteoblast differentiation. As shown in supplemental figures 1 
and 2, osteocalcin, alkaline phosphatase and Wnt10b were induced significantly in the 
IGFBP-2 overexpressing cells compared to control cells on days 6 and 9, thereby reflecting 
the acceleration of differentiation. Osteopontin was significantly increased at day 9. Runx2 
and osterix whose expression peaks early in differentiation declined between days 3 and 9 in 
the control cells and were significantly decreased in the IGFBP-2 overexpression cells 
whereas following IGFBP-2 knockdown, their expression was increased compared to control 
cultures, suggesting that differentiation is delayed (Supplemental Fig 1 and 2).
Overexpression of IGFBP-2 reduced the amount of serum supplementation that was 
necessary to induce differentiation. For example the addition of 5% serum containing 
differentiation medium to IGFBP-2 transfected cells induced a similar level of cell 
differentiation compared to control cells exposed to 10% serum (Supplemental Fig 3A). 
IGF-I stimulated differentiation of control and IGFBP-2 overexpressing cells but the 
percentage of cells that differentiated remained significantly greater in the IGFBP-2 
overexpressing cells (Supplemental Figure 3B and C). These results strongly suggest that 
IGFBP-2 is able to stimulate preosteoblast differentiation and that it is one of the factors that 
is present in 10% FBS that induces these changes.
AKT and PI-3 kinase activation are required for osteoblast differentiation
Several sub clones of MC-3T3 cells were originally derived from mouse calvarial 
osteoblasts.(13) Among them: clone 4 cells (CL4 cells) were found to differentiate in the 
appropriate medium. Since previous studies have shown the importance of AKT activation 
for osteoblast differentiation(14), we determined the IGF-I-stimulated AKT activation 
response during differentiation. The results showed that AKT Ser473 phosphorylation was 
stimulated by IGF-I during differentiation phase in MC-3T3, CL4 cells (Fig 2A). A clone of 
MC-3T3 cells derived from the same parental cell line (CL24) is unable to differentiate. 
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When these cells were analyzed neither basal nor IGF-I-stimulated AKT Ser473 
phosphorylation could be detected after several days in differentiation medium (Fig 2A). 
Importantly, overexpression of IGFBP-2 enhanced IGF-I stimulated AKT activation (Fig 
2A)
In order to determine the time point in the differentiation cycle wherein PI-3 kinase 
activation was required to induce preosteoblast differentiation, the PI-3 kinase inhibitor, LY 
294002, was utilized. The results show that inhibition of PI-3 kinase completely prevented 
differentiation when the inhibitor was applied on day 3 following the addition of 
differentiation medium (Fig 2B). It also significantly suppressed differentiation when it was 
applied on day 6. However if it was applied after day six the inhibitory effect was minimal at 
day 9 and completely lost by day 12 or later (Fig 2B). When this experiment was repeated 
using cells overexpressing IGFBP-2, differentiation was detectible and was attenuated when 
the inhibitor was added on day 1 or day 3 but it was not altered if the inhibitor was added at 
day 6 or later (Fig 2C).
Since inhibition of PI-3 kinase activation prevented differentiation, we examined the time 
course of AKT phosphorylation at different time points during differentiation in control and 
IGFBP-2 overexpressing cells. AKT activation was minimal at day 3 in control cells but it 
was increased significantly in the overexpressing cells (Fig. 2D). (e.g., to a level that was 7.5 
fold greater at day 3, p<0.001). These results are consistent with the differences in 
osteocalcin expression shown in Fig 1G. When AKT activation was analyzed in primary 
osteoblasts that were obtained from IGFBP-2 −/− mice there was a significant reduction in 
constitutive pAKT expression compared to cells from control +/+ animals on days 3, 6 and 9 
(Fig 2E) (e.g., to a level that was 3.1 ± 0.4 fold less than osteoblasts from +/+ mice at day 9, 
p<0.01). Importantly the differences in constitutive AKT activation correlated with those 
detected in osteocalcin expression (Fig 1D).
IGFBP-2 enhances AKT activation via suppressing RPTPβ dephosphorylation of PTEN
Our previous study in smooth muscle cells showed that IGFBP-2 enhances IGF-I-stimulated 
AKT activation via direct binding of IGFBP-2 to RPTPβ which catalyzes its polymerization 
and thereby inhibits its ability to dephosphorylate PTEN.(9) That study also showed that 
MC-3T3 cells expressed RTPTβ and that IGFBP-2 exposure increased PTEN tyrosine 
phosphorylation. Since tyrosine phosphorylation of PTEN attenuates its ability to inhibit 
AKT activation, this results in an enhancement of constitutive and IGF-I-stimulated AKT 
phosphorylation. RPTPβ expression increases during osteoblast differentiation(15), therefore 
we hypothesized that IGFBP-2 enhanced AKT activation during osteoblast differentiation 
through this same mechanism. To test this hypothesis we first examined whether IGFBP-2 
overexpression and IGF-I addition stimulated IGFBP-2/RPTPβ association during 
differentiation. The results showed that the formation of the IGFBP-2/RPTPβ complex was 
detected on day 6 in control cultures (Fig 3A). This is consistent with the level of 
constitutive AKT activation (Fig 2D). Following IGF-I stimulation, complex formation 
increased in control cells and, in cells overexpressing IGFBP-2, there was an increase in 
basal and IGF-I stimulated IGFBP-2/RPTPβ association on days 3 and 6 compared to 
control cells (Fig 3A) (e.g., 3.6 ± 0.9 fold and 2.6 ± 0.1 fold increases in IGF-I stimulated 
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complex formation in IGFBP-2 overexpressing cells compared to LacZ cells on days 3 and 
6, p<0.05, respectively). Correspondingly PTEN tyrosine phosphorylation was increased in 
the IGFBP-2 overexpressing cells compared to control cells on days 3 and 6 (Fig 3B). To 
directly determine the role of RPTPβ on osteoblast differentiation, we manipulated the 
RPTPβ level in MC-3T3 cells. Knockdown of RPTPβ during the differentiation phase 
enhanced basal and IGF-I stimulated PTEN tyrosine phosphorylation as well as AKT 
activation (Fig 3C) (e.g., a 2.3 ± 0.2 fold greater level of pAKT expression in RPTPβ Si cells 
compared to control, p<0.05). Further analysis showed that osteocalcin expression was 
enhanced on days 9, 12, and 21 (Fig 3D) as well as cell differentiation on days 15, 18 and 21 
compared to control cultures (Fig 3E). In contrast overexpression of RPTPβ inhibited PTEN 
tyrosine phosphorylation (Fig 3F) and impaired osteoblast differentiation (Fig 3G).
We have shown previously that IGFBP-2 binding to RPTPβ induces polymerization which 
inhibits its phosphatase activity. When IGFBP-2 was added back to the RPTPβ 
overexpressing cells there was enhanced osteocalcin expression at day 12 and this also 
rescued differentiation (Fig 3H). Correspondingly the addition of IGFBP-2 enhanced basal 
(e.g., a 3.9 ± 0.4 fold greater compared to control, p<0.01) and IGF-I-stimulated AKT 
phosphorylation (e.g., a 1.7 ± 0.2 fold greater compared to no IGFBP-2 treatment, p<0.05) 
(Fig 3I). These results clearly show that IGFBP-2 regulation of RPTPβ activity plays an 
important role in preosteoblast differentiation and that RPTPβ regulates osteoblast 
differentiation through modulation of PTEN tyrosine phosphorylation.
Disruption of IGFBP-2/RPTPβ interaction impairs IGF-I-stimulated AKT activation and 
osteoblast differentiation
To confirm the importance of the IGFBP-2/RPTPβ interaction, MC-3T3 cells 
overexpressing IGFBP-2 were analyzed. Following the addition of IGF-I there was a 
significant increase in IGFBP-2/RPTPβ association (Fig 4A) (e.g., a 2.5 ± 0.2 fold greater 
level of complex formation in IGFBP-2 overexpressing cells compared to control cells p< 
0.05). To inhibit this interaction we utilized an anti-RPTPβ blocking antibody and 
determined its effect on the IGFBP-2/RPTPβ interaction, downstream signaling and 
differentiation. The antibody inhibited IGF-I stimulated IGFBP-2/RPTPβ association in 
control and IGFBP-2 overexpressing cells (Fig 4A). Disruption of their interaction was 
functionally significant since it inhibited AKT activation (Fig 4B) and osteocalcin 
expression (Fig 4C) (e.g., 74 ± 8% reduction in osteocalcin with 500ng/ml, p<0.01). Since 
IGF-I stimulates IGFBP-2/RPTPβ association that is critical for AKT activation(9) and 
osteoblast differentiation, we determined whether the requirement for IGF-I was changed 
when IGFBP-2 was overexpressed. To block IGF-I signaling, PQ401, a specific inhibitor of 
IGF-I receptor tyrosine kinase was used. The results show that PQ401 treatment 
significantly impaired osteocalcin expression and cell differentiation in IGFBP-2 
overexpressing cells (Fig 4D and E).
HBD-1 peptide mediates the IGFBP-2 effect on osteoblast differentiation
The HBD-1 domain of IGFBP-2 mediates its stimulatory effect on osteoblast 
proliferation.(4) To investigate the importance of the HBD-1 domain for osteoblast 
differentiation, we utilized an IGFBP-2 mutant in which the charged amino acids within the 
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HBD-1 sequence were changed to alanine and an 13 amino acid synthetic peptide that 
contained this sequence and examined their abilities to alter the differentiation of calvarial 
preosteoblasts isolated from IGFBP-2 null mice. The results show that unlike wild type 
IGFBP-2 when the HBD-1 mutant form of IGFBP-2 was added, its ability to stimulate 
preosteoblast differentiation was significantly impaired (Fig 5A). To further investigate the 
function of HBD-1 domain, an HBD-1 peptide was added to differentiation medium. The 
peptide was able to rescue IGFBP-2 −/− cell differentiation (Fig 5A). When the results were 
quantified the differences were significant (Fig 5A). When increasing concentrations of the 
HBD-1 peptide were added a substantial increase in the percentage of cells that 
differentiated was noted at 500 ng/ml and it increased further with 1000 ng/ml (Fig 5B). 
When osteocalcin expression was analyzed this effect was confirmed and there was an 
incremental increase between 250 and 1000 ng/ml (Fig 5C). To determine whether HBD-1-
enhanced cell differentiation was due to change of cell survival, we measured the cleaved 
caspase-3, an indicator for cell apoptosis. The results showed that the HBD-1 peptide had no 
effect on osteoblast apoptosis (Supplemental Figure 4A).
Discussion
Although IGFBP-2 functions with IGF-II to increase bone mass(16), and IGFBP-2 knockout 
mice have decreased cortical and trabecular bone(3–4), the specific role of IGFBP-2 in 
modifying osteoblast differentiation has not been reported. Prior studies showed that 
IGFBP-2 enhances the effect of both IGF-I and IGF-II in stimulating bone accretion in 
vivo.(4,16) Subsequently we showed that a peptide containing the HBD-1 sequence rescues 
the normal bone phenotype in IGFBP-2 −/− mice and that this peptide stimulated osteoblast 
proliferation.(4) These studies extend those findings to demonstrate that the HBD-1 peptide 
as well as intact IGFBP-2 stimulates osteoblast differentiation. The results clearly 
demonstrate that overexpression of IGFBP-2 results in acceleration of the differentiation 
program as well as increasing the total number of cells reaching the stage of mature 
osteoblast formation. Proteins that are markers of differentiation, such as osteocalcin, are 
increased in response to IGFBP-2 and they are expressed earlier in the differentiation 
program following IGFBP-2 stimulation. The results show that the expression of Wnt10b, 
alkaline phosphatase and osteopontin were increased in a similar manner. The effect of 
IGFBP-2 is mediated through the cell surface receptor RPTPβ since addition of an antibody 
which inhibited its binding to this receptor significantly attenuated its ability to stimulate 
signaling events that are linked to osteoblast differentiation. Moreover, knockdown of this 
receptor inhibited the ability of IGFBP-2 to stimulate differentiation.
That the HBD-1 domain was important for signaling within the intact protein was confirmed 
using site directed mutagenesis. Specifically addition a mutant with an altered HBD-1 
sequence resulted in attenuated differentiation. Both the time course and the absolute 
number of cells as well as expression of osteocalcin were deceased. Our prior studies 
showed that an 13 amino acid peptide containing the HBD-1 sequence stimulated trabecular 
bone formation in IGFBP-2 −/− mice.(4) Keipe et al(17) demonstrated that a 117 amino acid 
carboxy terminal fragment of IGFBP-2 that would have contained the HBD-1 sequence 
exerted a strong mitogenic effect on growth plate chondrocytes and the effect was equal to 
intact IGFBP-2. These studies extend those observations to show that a peptide 
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encompassing the sequence of HBD-1 is sufficient to stimulate osteoblast differentiation 
through its interaction with RPTPβ.
Our prior study showed that RPTPβ was present on the surface of MC-3T3 cells and that 
IGFBP-2 could interact with this protein to alter PTEN tyrosine phosphorylation.(9) 
IGFBP-2 stimulated RPTPβ polymerization thereby attenuating its phosphatase activity. 
Since PTEN is a RPTPβ substrate, this resulted in increased tyrosine phosphorylation of 
PTEN which attenuated PTEN enzymatic activity thereby leading to increased AKT 
phosphorylation. These studies extend those observations showing that enhancement of 
constitutive AKT phosphorylation occurs concomitantly with earlier differentiation in cells 
that overexpress IGFBP-2 and that these responses are attenuated when IGFBP-2 expression 
is diminished. That these changes are mediated through RPTPβ was proven by 
demonstrating that inhibition of IGFBP-2 binding to RPTPβ could block enhanced AKT 
activation and differentiation, and that knocking down of RPTPβ resulted in escape from its 
ability to inhibit AKT activation as well as a reduction in cell responsiveness to intact 
IGFBP-2. The studies also demonstrated that constituently synthesized IGFBP-2 is 
important for osteoblast differentiation. Knockdown of constituently synthesized IGFBP-2 
resulted in attenuation of differentiation and expression of osteocalcin as well as constitutive 
AKT phosphorylation. Addition of an antibody that inhibits the binding of IGFBP-2 to 
RPTPβ could attenuate these responses in non-transfected MC-3T3 cells. Therefore, these 
results further support the conclusion that IGFBP-2 functions by attenuating RPTPβ 
mediating PTEN dephosphorylation and stimulating AKT activation, leading to enhanced 
osteoblast differentiation. The importance of AKT activation for differentiation was also 
shown by inhibiting PI-3 kinase, which is upstream of AKT. The addition of a PI-3 kinase 
inhibitor, after 3 day exposure to differentiation medium, completely prevented osteoblast 
differentiation. However, to obtain similar level of inhibition in IGFBP-2 overexpressing 
cells the inhibitor needed to be added at an earlier time point.
Since previous studies have also shown that suppression of MAP kinase activation 
stimulated osteoblast differentiation,(14,18–19) we also analyzed MAP kinase activation using 
a similar experimental paradigm. Consistent with prior reports, our results showed that 
inhibition of MAP kinase activation significantly stimulated osteoblast differentiation, 
however, this stimulation was only detected when inhibitor was added at the early stage of 
cell differentiation, such as on day 3 and day 6 (Supplemental Fig 4B). Importantly, over-
expression of IGFBP-2 did not significantly alter MAP kinase activation, compared to 
control cells (Supplemental Fig 4C), indicating that MAP kinase pathway did not play an 
important role in mediating the stimulatory effect of IGFBP-2 on osteoblast differentiation. 
Consistently, exogenous addition of a peptide containing HBD-1 sequence or IGFBP-2 or 
overexpression of IGFBP-2 had no significant effect on cell proliferation in the 
differentiation medium (Supplemental Fig 4D and E).
Other studies have suggested that expression of IGFBP-2 correlates with changes in 
osteoblast differentiation although they have not shown the direct causal links reported 
herein. Specifically Kawase et al induced chondrocytes sheets to differentiate into 
osteoblasts and showed increased secretion of both IGF-I and IGFBP-2 that occurred during 
deposition of osteoid and mineralized tissue.(6) Similarly, Hamidouche et al. demonstrated 
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that induction of osteoblast differentiation from mesenchymal stromal cells was 
accompanied by an increase in the synthesis of IGF-II, IGFBP-2 and the α5 integrin 
subunit.(8) Both IGF-II and IGFBP-2 were shown to increase the expression of phenotypic 
markers as well as the in vitro osteogenic capacity of the cells. They also demonstrated that 
downregulation of the α5 subunit decreased IGF-II and IGFBP-2 expression and that their 
expression was dependent on constituitive integrin α5 activation suggesting a link between 
increased IGFBP-2 synthesis and differentiation. Lee et al showed that treatment of 
mesenchymal stem cells during osteoblast induction with parathyroid hormone resulted in 
increased expression of IGF-I, IGF-II and IGFBP-2 whereas PTH treatment of cord blood 
derived the stem cells that did not differentiate into osteoblasts did not show these 
changes.(7) These findings have been extended to human osteoblasts wherein it was 
demonstrated that IGFBP-2 and IGF-I or II expression are upregulated during in vitro 
induction of differentiation and that this correlated negatively with proliferation.(20) Palermo 
et al showed that IGF-II stimulated IGFBP-2 synthesis in tibial osteoblast cultures during 
differentiation and that IGFBP-2 was the most abundant form of IGFBP that was induced.(2) 
Thraikill et al reported that MC-3T3 cells increased IGFBP-2 expression between days 10 
and 14 of differentiation: concomitant with the onset of osteocalcin expression.(21) Several 
factors that have been shown to stimulate IGFBP-2 expression by MC-3T3 cells specifically 
phorbol esters(22) and FGF(23). A more recent study by Yerges et al demonstrated that 
IGFBP-2 SNPs were associated with lumbar volumetric bone mineral density in humans and 
that only 7 genes were found to be this tightly associated.(24)
Other cell types have also been analyzed to determine the role of IGFBP-2 in differentiation. 
In hematopoetic stem cells IGFBP-2 supports stem cell expansion but no specific 
mechanism by which it stimulates differentiation in this cell type has been defined.(25–26) 
Knockdown of IGFBP-2 in zebrafish embryos resulted in disruption of cardiac development 
and impaired differentiation of cardiomyocytes.(27) Additionally there were vessel sprouting 
defects which suggested a role in angiogenesis and endothelial cell differentiation. Our 
studies have demonstrated that IGFBP-2 expression is required for osteoclast 
differentiation.(28) Cells derived from IGFBP-2 −/− mice showed minimal osteoclast 
differentiation which could be rescued with exogenous addition of IGFBP-2. The defect 
appeared to be an inability to form mature osteoclasts that retain full bone resorbing activity. 
The role of IGFBP-2 in differentiation has been intensively studied in skeletal myoblasts 
wherein it has been demonstrated that the addition of differentiation medium to myoblasts in 
culture results in a major increase in expression of IGFBP-2 and inhibition of IGFBP-2 
using neutralizing antibodies inhibits myoblast differentiation.(29) Therefore it appears that 
IGFBP-2 coordinately regulates the ability of IGF-I and IGF-II stimulate differentiation in 
several cell types.
Numerous studies have shown a positive effect of IGF-I on bone formation in vivo and on 
osteoblast differentiation in vitro. Addition of IGF-I to culture medium with BMP-2 
enhanced osteoblast differentiation and this effect was believed to be mediated through 
AKT.(30) Yeh et al. demonstrated that BMP-2 and IGF-I induced a synergistic increase in 
osteoblast differentiation and that this response could be inhibited by a protein kinase D 
inhibitor.(31) IGF-I also mediates chondrocyte differentiation and mature chondrocytes can 
differentiate into osteoblasts therefore this indirectly alters osteoblast differentiation.(32) 
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Similarly IGF-II has been shown to enhance osteogenic differentiation and it directly 
potentiates the effects of BMP 9 on alkaline phosphatase activity.(33) These effects are 
inhibited by PI-3 kinase inhibitors suggesting the AKT pathway that is the primary mediator. 
Matrix IGF-I has been shown to maintain bone mass by enhancing osteoblast differentiation. 
This effect required concomitant injection of IGFBP-3 which improved bone matrix 
localization.(10) Our current study also showed that blockage of IGF-I signaling significantly 
impaired osteoblast differentiation even though IGFBP-2 was overexpressed. We conclude 
that IGF-I and IGFBP-2 function coordinately to stimulate differentiation and both peptides 
are required for an optimal stimulation.
Transgenic mice that overexpress IGF-I in osteoblasts have increased trabecular bone and 
increased bone formation.(34) Conditional IGF-I receptor null mice showed decreased 
osteoblast number and reduced trabecular volume and impaired differentiation and 
calcification(35) and locally produced skeletal IGF-I plays an important role in trabecular 
bone integrity.(36) Since IGFBP-2 stimulates trabecular bone formation and osteoblast 
differentiation, our results suggest that the two proteins are functioning coordinately. This 
conclusion is supported by the observation that PTH is a potent stimulant of not only IGF-I 
synthesis in bone but it also induces IGFBP-2.
In conclusion, the results of our studies suggest that IGFBP-2 functions to enhance the 
ability of IGF-I to stimulate osteoblast differentiation and that this effect is specific for 
IGFBP-2. Since IGF-I can stimulate both osteoblast proliferation and differentiation, our 
findings suggests that IGFBP-2 may function directly to coordinate these responses and 
independently of its transport capacity for the IGFs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. IGFBP-2 stimulates osteoblast differentiation
(A) Equal amounts of cell lysate from MC-3T3 cells expressing a shRNA sequence targeting 
LacZ (Ctrl Si) or IGFBP-2 (IGFBP-2 Si) were immunoblotted with indicated antibody. β-
actin was immunoblotted as a loading control. (B) Cell lysate from Ctrl Si or IGFBP-2 Si 
cells on the indicated day after differentiation medium (DM) exposure were immunoblotted 
with the indicated antibody. (C) Ctrl Si or IGFBP-2 Si expressing cells were stained by 
Alizarin Red following the procedure described in “Materials and Methods” on indicated 
day after DM exposure. (D) Cell lysates from IGFBP-2−/− or IGFBP-2 +/+ derived calvarial 
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osteoblasts prepared on indicated day after DM exposure were immunoblotted with 
indicated antibody. The bar graph shows the ratio of scanning densitometry units of 
osteocalcin/β-actin obtained from three individual experiments. (E) Calvarial osteoblasts 
isolated from IGFBP-2 +/+ or IGFBP-2 −/− mice were exposed to DM alone or DM plus 
IGFBP-2 (1 ug/ml) and stained with Alizarin Red on day 21. (F) Lysates from cells 
expressing LacZ or IGFBP-2 were immunoblotted with indicated antibody. (G) Lysates from 
cells expressing LacZ or IGFBP-2 on indicated day after DM exposure were immunoblotted 
with indicated antibody. β-actin was immunoblotted as a loading control. The bar graphs 
show the ratio of scanning densitometry units of osteocalcin/β-actin obtained from three 
individual experiments. (H) Cells expressing LacZ or IGFBP-2 were stained with Alizarin 
Red on indicated day after DM exposure.
Xi et al. Page 17













Figure 2. AKT activation is required for osteoblast differentiation
(A) Lysates obtained from MC-3T3 cells, clone 24 (CL24) or clone 4 (CL4) on day 6 after 
DM exposure were immunoblotted with indicated antibody. Lysates from quiescent cells 
expressing LacZ or IGFBP-2 on day 6 after DM exposure were immunoblotted with the 
indicated antibody. Wild type MC-3T3 cells (B) or IGFBP-2 overexpressing cells (C) were 
stained by Alizarin Red on day 21 after differentiation medium (DM) alone or DM plus 
LY294002 which was added on the indicated day. The medium was changed every 72hr. (D) 
Lysates obtained from cells overexpressing IGFBP-2 or LacZ after indicated day of DM 
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exposure were immunblotted with indicated antibody. The bar graph shows the ratio of 
scanning densitometry units of pAKT/β-actin obtained from three individual experiments. 
(E) Lysates from IGFBP-2−/− or IGFBP-2 +/+ derived calvarial osteoblasts obtained on 
indicated day after DM exposure were immunoblotted with indicated antibody. The bar 
graph shows the ratio of scanning densitometry units of pAKT/β-actin obtained from three 
individual experiments.
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Figure 3. IGFBP-2 enhances AKT activation via suppressing RPTPβ dephosphorylation of 
PTEN
(A) Cell lysates from quiescent LacZ or IGFBP-2 overexpressing cells were 
immunoprecipitated with an anti-IGFBP-2 antibody and immunoblotted with an anti-RPTPβ 
antibody. β-actin was immunoblotted as a loading control. (B) Lysates from LacZ or 
IGFBP-2 overexpressing cells on indicated day after differentiation medium (DM) exposure 
were immunoprecipated with an anti-PY99 antibody and immunoblotted with an anti-PTEN 
antibody. PTEN was immunoblotted as an input control. (C, D) Lysates from MT-3C3 cells 
expressing shRNA sequence targeting LacZ (Ctrl Si) or RPTPβ (RPTPβ Si) were 
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immunoblotted with the indicated antibodies. (E) Cells expressing Ctrl Si or RPTPβ Si were 
stained by Alizarin Red on indicated day after DM exposure. (F) Lysates from LacZ or 
RPTPβ overexpressing cells were immunoblotted with anti-HA and β-actin antibodies. The 
same cell lysates were immunoprecipitated with an anti-PY99 antibody and immuoblotted 
with an anti-PTEN antibody. PTEN was immunoblotted as an input control. (G) Cells 
expressing LacZ or RPTPβ were stained by Alizarin Red on indicated day after DM 
exposure. (H) Cells expressing RPTPβ were stained by Alizarin Red on day 21 after DM 
alone or DM plus IGFBP-2 exposure. Lysates from the same RPTPβ overexpressing cultures 
were immunoblotted with anti-osteocalcin and β-actin antibodies. (I) Lysates from quiescent 
RPTPβ overexpressing cells obtained on day 6 after IGF-I alone or IGFBP-2 alone (1ug/ml) 
or IGF-I plus IGFBP-2 (1 ug/ml) were immunoblotted with anti-pAKT and β-actin 
antibodies.
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Figure 4. Disruption of IGFBP-2/RPTPβ interaction impairs IGF-I-stimulated AKT activation 
and osteoblast differentiation
(A) Lysates from quiescent LacZ or IGFBP-2 overexpressing cells obtained on day 6 after 
differentiation medium (DM) exposure treated with or without IGF-I alone (10 min) or IGF-
I following a 4 hr exposure to anti-fibronectin domain (FN3) antibody were 
immunoprecipitated using an anti-IGFBP-2 antibody and immunoblotted with an anti-
RPTPβ antibody (B) Lysates from quiescent IGFBP-2 overexpressing cells that received the 
same treatments as in panel A were obtained on Day 6 after DM exposure and were 
immunoblotted with indicated antibody. (C) Lysates from LacZ overexpressing cells 
obtained on day 21 after DM exposure following incubation with the indicated concentration 
of anti-fibronectin antibody (FN3) were immunoblotted with anti-osteocalcin and anti-β-
actin antibodies. (D) Lysates from IGFBP-2 overexpressing cells obtained on day 9 and 12 
after DM exposure following incubation with PQ401 (10 uM) were immunoblotted with 
anti-osteocalcin and anti-β-actin antibodies. (E) Cells expressing IGFBP-2 that had been 
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incubated with or without PQ401 were stained with Alizarin Red on day 18 after DM 
exposure.
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Figure 5. The heparin binding domain-1 (HBD-1) mediates the IGFBP-2 effect on osteoblast 
differentiation
(A) Calvarial osteoblasts isolated from IGFBP-2 +/+ or IGFBP-2 −/− mice were exposed to 
differentiation medium (DM) alone, DM plus IGFBP-2 (1 ug/ml), DM plus control peptide 
(Ctrl Pep, 1 ug/ml), DM plus HBD-1 (1 ug/ml) or DM plus the HBD-1 IGFBP-2 mutant 
protein (IGFBP-2 MP, 1 ug/ml) then stained with Alizarin Red on day 21. The bar graph 
shows the percentage of stained area that was quantified using NIH Image J (1.47n). (B, C) 
Calvarial osteoblasts isolated from IGFBP-2 −/− mice were exposed to DM alone (Ctrl) or 
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DM plus the indicated concentration of HBD-1 peptide for 21 days and stained with Alizarin 
Red (B). Cell lysates were immunoblotted with anti-osteocalcin and β-actin antibodies (C).
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